Author | T. E. Witzig


Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

March 01, 2001

ByT. E. Witzig|Leo I. Gordon, MD|G. A. Wiseman|S. Spies|C. Emmanouilides|Myron S. Czuczman, MD|I. W. Flinn|N. L. Barlett|J. L. Murray|B. Alkuzweny|Pratik S. Multani, MD|A. J. Grillo-Lopez, MD|Christine A. White, MD

Ibritumomab tiuxetan (Zevalin) consists of an anti-CD20 murine IgG1 kappa monoclonal antibody covalently bound to tiuxetan (MX-DTPA), which stably chelates yttrium-90 for therapy. Ibritumomab tiuxetan therapy involves pretreatment with